abstract: Rare cells with adult stem cell activity were recently discovered in human endometrium. Endometrial stem/progenitor cell candidates include epithelial, mesenchymal and endothelial cells, and all may contribute to the rapid endometrial regeneration following menstruation, rather than a single candidate. Endometrial mesenchymal stem-like cells (eMSC) are prospectively isolated as CD146
Introduction

Adult stem cells
Adult stem cells are rare undifferentiated cells present in most adult tissues. Adult stem cells have been identified in a wide variety of tissues and organs in recent years by demonstration of their defining functional properties. These are self-renewal, differentiation into one or more lineages and high proliferative potential (Eckfeldt et al., 2005) . Other functional properties of adult stem cells include clonogenicity or colony forming unit (CFU) activity, Hoechst 33342 exclusion to identify the side population (SP cells), tissue reconstitution in vivo and DNA synthesis label (bromodeoxyuridine, BrdU) retention for identifying label-retaining cells (LRC) (Gargett, 2007) . These functional analyses identify adult stem cell activity when defining markers for these cells are unknown. Ongoing research, however, continues to focus on identifying markers of adult stem cells, although few are specific or defining. Adult stem cells maintain tissue homeostasis though provision of replacement cells in routine cellular turnover and for repairing injured tissues (Li and Xie, 2005) . The stem cell niche, comprising the adult stem cell, surrounding niche cell(s) and extracellular matrix regulates adult stem cell fate decisions, balancing stem cell replacement (self-renewal) and provision of functional differentiated cells required for organ function (Li and Xie, 2005) . The stem cell niche provides a protective environment for the resident stem cell to maintain its genetic fidelity over its lifespan, and at the same time maintaining its capacity to rapidly respond to tissue needs for cellular replacement.
Endometrial regeneration and the stem cell hypothesis
Human endometrium is structurally and functionally divided into two major regions. The functionalis, comprising the upper two-thirds contains glands extending from the surface epithelium to the endometrial/ myometrial junction, is composed of a pseudo-stratified columnar epithelium surrounded by a loose vascularized stroma. The functionalis is shed during menses. The lower basalis containing the basal region of the glands, dense stroma and large vessels remains and serves as a germinal compartment for generating the new functionalis each month (Spencer et al., 2005) . The human endometrium is a dynamic remodelling tissue undergoing more than 400 cycles of regeneration, differentiation and shedding during a woman's reproductive years (Jabbour et al., 2006; Gargett, 2007) . Each month 4-10 mm of mucosal tissue grows within 4-10 days in the proliferative stage of the menstrual cycle under the influence of increasing circulating estrogen levels. Endometrial regeneration also follows parturition resection of the endometrium and occurs in post-menopausal women taking estrogen replacement therapy (Gargett, 2006; Gargett, 2007) . In non-menstruating species (e.g. rodents), the endometrium undergoes cycles of growth and apoptosis during the estrus cycle, rather than physical shedding (Gargett, 2007) . This level of new tissue growth is similar to the cellular turnover in the highly regenerative bone marrow haemopoietic tissue, the epidermis and intestinal epithelium. Adult stem cells are responsible for cellular production in these continuously regenerating tissues. It has been hypothesized that adult stem or progenitor cells are responsible for the cyclical regeneration of the endometrial functionalis each month, and that these adult stem cells reside in the basalis, and are present in the atrophic endometrium of post-menopausal women (reviewed in Gargett, 2007) .
Epithelial stem/progenitor cells in the endometrium
CFUs/cells as epithelial progenitors in human endometrium
Cell cloning studies of human endometrial cells provided the first evidence for the existence of endometrial epithelial progenitor cells (Chan et al., 2004) . In these studies, 0.2% of single cell suspensions of epithelial cell adhesion molecule + (EpCAM + ) cells freshly isolated from hysterectomy tissues had CFU activity, with 0.09% forming large CFU and 0.14% forming small CFU. Endometrial epithelial CFU could be cultured in serum-free medium containing either epidermal growth factor (EGF) or transforming growth factor-a (TGF-a), suggesting that they express EGF receptors (Chan et al., 2004; Schwab et al., 2005; Gargett, 2006) . Mouse fibroblast feeder layers were required for serum-free clonal culture, indicating the importance of the stem cell niche for endometrial epithelial progenitor cell activity. Subsequent studies on epithelial CFU indicated that individual large CFU had substantial self-renewal activity in vitro, undergoing serial subcloning 2.9 times at very low seeding densities (10 cells/cm 2 ), whereas small CFU subcloned 0.5 times . The large epithelial CFU had high proliferative potential undergoing 34 population doublings when cultured at bulk culture densities (2000 cells/cm 2 ), generating 6 × 10 11 cells from a single cell, while small CFU produced six orders of magnitude fewer cells. Large epithelial CFU also differentiated into large cytokeratin-expressing gland-like structures when cultured in Matrigel Fig. 1) . The ability of large epithelial CFU to self-renew and differentiate suggest they are initiated by epithelial progenitor cells which we hypothesize reside in the basalis near the base of the glands ( Fig. 2A) , whereas small CFU may be initiated by more mature transit-amplifying cells, likely resident in the functionalis and responsible for the extensive epithelial proliferation observed in the first half of the menstrual cycle.
LRC as adult stem cells in mouse endometrial epithelium
Epithelial LRC have been identified as candidate adult stem cells in vivo in mouse endometrium . The LRC approach is used to identify adult stem cells when specific markers are unknown, and relies on the relatively infrequent cell turnover of most adult stem Endometrial stem/progenitor cells cells in comparison to rapidly proliferating transit-amplifying cells Gargett, 2007; Gargett et al., 2007) . LRC are detected by pulse-labelling the majority of tissue cells with a DNA synthesis label (BrdU) when adult stem cells are proliferating, and subsequently chasing out the label over long periods of time.
With each cell division the incorporated BrdU is diluted 50% until it reaches undetectable levels after 3-4 cell divisions. Immunohistochemistry localizes BrdU + LRC, revealing their location and the stem cell niche. BrdU labelling during the post-natal period (Days 3-5) showed that LRC comprised 3% of mouse endometrial epithelial cells, which were located in the luminal rather than the glandular epithelium as single well-separated cells that did not express estrogen receptor-a (ERa), suggesting that luminal epithelial stem/progenitor cells are responsible for the growth of glands during development and in cycling mice (Fig. 2B; Chan and Gargett, 2006) . In ovariectomized prepubertal mice, the first cells to proliferate in estrogenstimulated endometrial growth are the epithelial LRC, suggesting that they function as stem/progenitor cells to initiate epithelial regeneration . However, in ovariectomized cycling mice, both epithelial LRC and non-LRC rapidly proliferated in response to estrogen to regenerate luminal and glandular epithelium . Application of the LRC technique to a mouse model of menstrual breakdown and repair (Kaitu'u-Lino et al., 2010) showed that in adult female mice labelled with BrdU, ERa negative glandular epithelial LRC may contribute to repair of the luminal epithelium when it is sloughed off in response to progesterone withdrawal (Fig. 3 ). In this model, endometrial repair occurs in the absence of estrogen (Kaitu'u-Lino et al., 2007) . These various models of endometrial epithelial growth and repair suggest that LRC may reside in luminal or glandular epithelium at different stages of murine endometrial development, and that luminal LRC may have an important role in generating luminal epithelium during development, while glandular LRC have a key role in replenishing shed or lost luminal epithelium, as is expected for human endometrium.
Monoclonality of endometrial glands suggests that progenitor cells reside in their bases
Monoclonality of single glands has been demonstrated by PCR for the X-linked androgen receptor gene (HUMARA assay), which undergoes random X-linked inactivation (Tanaka et al., 2003) , and by lack of PTEN immunostaining in rare individual glands (Mutter et al., 2000) . The HUMARA assay showed that adjacent glands shared clonality for areas up to 1 mm, indicating that well-circumscribed regions of the endometrium were derived from the same precursor and that single epithelial progenitor cells generated several glands, raising questions on the precise locality of these progenitor cells. PTEN immunostaining revealed that normal human endometrium contains rare glands that fail to express this tumour suppressor gene due to a mutation and/or deletion (Mutter et al., 2000) . The PTEN-null gland clones persist in the basalis region generating more PTEN-null glands in the functionalis in subsequent cycles. Under conditions of unopposed estrogen stimulation of the endometrium (e.g. endometrial hyperplasia), the proportion of PTEN-null glands increases since PTEN is an estrogen responsive gene (Mutter et al., 2001) . Monoclonal endometrial glands have been identified in the endometrium of chimeric mice (Lipschutz et al., 1999) , carrying the GFP-gene on the X chromosome. In these mice, individual endometrial glands were either GFP + or GFP 2 and the surface epithelium showed clear demarcation of GFP positive and negative regions (Tanaka et al., 2003) . Together these observations suggest that epithelial stem/progenitor cells reside in the bases of individual glands ( Fig. 2A ) that may be responsible for generating single glandular units or a region comprising several glands.
Endometrial epithelial progenitor cells inferred from gland methylation patterns
Methylation patterns of genes in individual glands of human endometrium have revealed the ancestry of epithelial stem/progenitor cells (Kim et al., 2005) . Epigenetic marks arising during adult stem cell division are inherited by all the daughter cells and persist, while those arising in the transit-amplifying or more mature cells are lost when the functionalis layer is shed during menstruation. The total number of stem cell divisions may be inferred from the numbers of epigenetic marks accumulated within individual glands (Ro and Rannala, 2001 ). The extent of gene methylation in endometrial glands increased with age until menopause, and then remained relatively constant, indicating that the number of epigenetic marks was a reflection of the mitotic activity of endometrial stem/progenitor cells (Kim et al., 2005) . Further mathematical analysis indicated that individual glands contain stem cell niches occupied by several long-lived stem cells. It would appear that symmetric and asymmetric cell divisions occurred in a stochastic manner to maintain a constant number of adult stem cells in the endometrial gland niche (Kim et al., 2005) arguing against the monoclonality concept.
Mesenchymal stromal/stem cells in the endometrium
Mesenchymal stromal cells (MSC) are defined as plastic adherent cells with a characteristic surface phenotype which can differentiate into osteoblasts, adipocytes and chondrocytes in vitro (Dominici et al., 2006) . MSC are found in numerous human tissues (Crisan et al., 2008) . A rare population of endometrial mesenchymal stem/stromal cells (eMSC) has been identified in human and mouse endometrium. These eMSC have properties and phenotype similar to bone marrow or adipose tissue MSC.
Stromal CFU as eMSC in human endometrium
In the same study identifying clonogenic epithelial cells, a small population of clonogenic stromal cells (1.25%) was isolated from the EpCAM 2 fraction of freshly isolated single cell suspensions of endometrial cells obtained from hysterectomy tissues of cycling women (Chan et al., 2004) . Clonogenic stromal cells were also observed in freshly isolated inactive endometrium of peri-menopausal or postmenopausal women and in women on oral contraceptives, suggesting that stromal CFU may be responsible for regenerating the endometrium when women commence estrogen replacement therapy or cease oral contraceptive treatment, respectively (Schwab et al., 2005; Gargett, 2006) . Similar to the clonogenic epithelial progenitor, two types of stromal CFU were generated, large (0.02%) and small (1.23%). Endometrial stromal CFU are clonogenic in serum-free medium supplemented with either fibroblast growth factor-2 (FGF2), EGF, TGF-a or platelet-derived growth factor-BB (PDGF-BB), suggesting that they express FGF receptors, EGFR and PDGF-Rb (Chan et al., 2004; Schwab et al., 2005) . Prior high density endometrial cell culture selects for clonogenic stromal cells, increasing their frequency to 15% (Dimitrov et al., 2008) . Subsequent studies of the large stromal CFU derived from freshly isolated hysterectomy endometrium demonstrated substantial selfrenewal ability in vitro, as they underwent serial subcloning 3.3 times when seeded at very low seeding densities (10 cells/cm 2 ), while small CFU serially cloned once Fig. 1 ; Gargett et al., 2009) . A population of cells differentiated into adipocytes (Dimitrov et al., 2008) , chondrocytes (Wolff et al., 2007) or dopaminergic neurons (Wolff et al., 2010) in passaged endometrial stromal cells and chondrogenic differentiation did not occur in myometrial, fibroid, Fallopian tube or uterosacral ligament cultures. CFU obtained from freshly isolated or cultured endometrial stromal cells expressed typical markers used to phenotype bone marrow and adipose tissue MSC; CD29, CD44, CD73, CD90, CD105, CD146 (Dominici et al., 2006) , but not STRO-1, CD31 (endothelial), CD34 (haemopoietic stem cell and endothelial), CD45 (leucocyte) or HLA-DR (Dimitrov et al., 2008; Gargett et al., 2009) . These studies indicate that multipotent eMSC with properties and phenotype similar to bone marrow and adipose tissue MSC are present in the highly regenerative endometrial stroma, but not in neighbouring reproductive tract tissues, suggesting that they may be responsible for regenerating the endometrial stroma in each menstrual cycle.
LRC as adult stem cells in mouse endometrial stroma
Candidate stromal stem/progenitor cells have been identified in mouse endometrium as stromal LRC Cervello et al., 2007; Szotek et al., 2007) . Between 6 and 9% of the stromal cells were identified as LRC, with many located near blood vessels close to the endometrial -myometrial junction ( Fig. 2B ) Cervello et al., 2007) , correlating with their postulated basalis location in human endometrium. The endometrial -myometrial junction is a site of cyclic tissue remodelling in both human (Fujii et al., 1989) and in a mouse model of menstruation and repair (Kaitu'u-Lino et al., 2007 . Stromal LRC are not leucocytes as they did not express CD45 .
Endometrial stem/progenitor cells Some (0.6%) expressed Oct-4, a pluripotency marker and c-kit, a haemopoietic stem cell marker (Cervello et al., 2007) , but in other studies, the stem cell markers Sca-1 or c-kit (Szotek et al., 2007) were not expressed. Most stromal LRC did not express ERa (84%) and one-third of stromal LRC expressed a-smooth muscle actin (aSMA) but not CD31, suggesting that they are pericytes or vascular smooth muscle cells and that they occupy a perivascular niche.
Tissue-reconstituting cells in human endometrium
Functional proof of adult stem cell activity in vivo is assessed by examining the ability of candidate endometrial adult stem cell populations to reconstitute endometrial tissue in xenografting experiments. Transplantation of fully dissociated unfractionated human endometrial epithelial and stromal cell suspensions (5 × 10 5 cells) directly beneath the kidney capsule of ovariectomized and estrogen-supplemented NOD/SCID/g c null (NOG) mice recapitulated well-organized endometrial and myometrial layers of functional endometrium comprising cytokeratin + CD9 + glandular structures, CD10 + CD13 + stroma and Masuda et al., 2007b) . This robust endometrial tissue reconstitution assay generated dozens of homogeneous xenografted mice from one sample. The endometrial xenografts responded to cyclical sex steroid hormones, forming tortuous glands and decidualized stroma when estrogen and progesterone were administered, as well as large blood-filled cysts after hormonal withdrawal reminiscent of menstruation ( Fig. 4D ; Masuda et al., 2007b) . As described below, the SP population similarly reconstituted endometrium when transplanted into NOG mice , demonstrating the utility of this assay to prove adult stem cell activity in isolated subpopulations of endometrial cells.
SP cells in human endometrium
Haemopoietic stem cells can be purified on the basis of differential staining of the fluorescent DNA binding vital dye, Hoechst 33342, using dual emission wavelength fluorescence activated cell sorting (FACS) (Goodell et al., 1997) . In the FACS histogram, a SP is separated from the majority of the cells as a low Hoechst population due to the ability of SP cells to efflux the dye through highly expressed ABCG2/Bcrp1 transporter proteins in the plasma membrane of adult stem cells ). ABCG2 was not essential for conferring stemness, but the SP phenotype is considered a universal marker of adult stem cell activity (Challen and Little, 2006) . SP cells (0-5%) have been identified in freshly isolated ( Fig. 5 ) (Tsuji et al., 2008; Cervello and Simon, 2009; Masuda et al., 2010) and short-term cultures (Kato et al., 2007) of human endometrial cells. Similar to CFU activity in human endometrium, the percentage of SP cells was highly variable between subjects, although higher numbers were found in the menstrual (Kato et al., 2007) and proliferative (Tsuji et al., 2008; Masuda et al., 2010) stages of the cycle (Fig. 5B ). Freshly sorted human endometrial SP cells showed little growth in culture, as most were in the G0 (85%) phase of the cell cycle, indicating their relative quiescence, a feature of adult stem cells. In contrast SP cells sorted from endometrial cultures were primarily in G1 and G1/M/S phases (Tsuji et al., 2008) . Endometrial SP cells, sorted from short-term cultures did not express endometrial epithelial (CD9) or stromal (CD13) cell differentiation markers, which were re-expressed in subsequent long-term Matrigel cultures indicating a capacity to differentiate into CD9 + E-cadherin + gland-like organoids and CD13 + stromal clusters (Kato et al., 2007) . Both SP and non-SP cells differentiated into prolactin-secreting decidual cells (Tsuji et al., 2008) . Clonogenic endometrial cells were enriched in the SP compared with the non-SP fraction (Tsuji et al., 2008) , although toxic levels of the Hoechst dye may affect CFU activity in non-SP cells. Further analysis indicates that human endometrial SP cells are a mixed population, comprising endothelial, epithelial and stromal cells (Tsuji et al., 2008; Masuda et al., 2010) . Immunostaining of full-thickness endometrial tissue for the SP marker ABCG2 revealed that ABCG2 + cells lined blood vessels distributed throughout the functionalis and basalis layers (Tsuji et al., 2008) , and co-localized with CD31 + endothelial cells (Fig. 5C and D; Masuda et al., 2010) . Interestingly, ABCG2 + cells are located adjacent to eMSC expressing PDGF-Rb and CD146 , indicating the importance of the vascular niche for endometrial stem/progenitor cells (Gargett, 2007) . Importantly, freshly isolated human endometrial SP cells, but not non-SP cells, reconstituted various endometrial tissue components and the entire endometrium when transplanted under the kidney capsule of immunocompromized NOG mice ( Fig. 5E ; Masuda et al., 2010) . Together these data indicate 
Source of endometrial stem/progenitor cells
Endometrial stem/progenitor cells may be derived from residual fetal stem cells (Gargett, 2007) , although several lines of evidence suggest that bone marrow cells may also populate the endometrium and contribute to the pool of resident adult stem cells (Table I) . Bone marrow stem cells, including haemopoietic stem cells, MSC and endothelial progenitor cells (Mayani et al., 2003; He et al., 2007; Robb et al., 2009) , circulate in very low numbers. Clinical and scientific evidence indicates that bone marrow stem cells and myeloid cells home to sites of tissue damage and incorporate into various organs, contributing to angiogenesis and/or transdifferentiating into the cells of the new tissue in which they reside (Korbling and Estrov, 2003; Du and Taylor, 2010b) . Transdifferentiation is the process whereby cells of one lineage are converted to a another lineage with loss of the original tissue-specific markers and function, and acquisition of markers and function of a new cell type (Tosh and Slack, 2002; Wagers and Weissman, 2004; Eberhard and Tosh, 2008) . Bone marrow MSC plasticity and transdifferentiation into epithelial or neural lineages remains controversial as individual studies report conflicting results in various models of tissue repair (Phinney and Prockop, 2007) . Lack of consensus may be explained in part by the heterogeneity of bone marrow MSC, which may comprise subpopulations with neural lineage capacity selected in the culture expansion process, or their inherent sensitivity to the microenvironment which may direct their differentiation across lineage boundaries (Phinney and Prockop, 2007) . Transplantation of exogenous MSC has confirmed that MSC home to damaged tissues (e.g. the ischaemic heart) where they contribute to repair through release of trophic factors rather than by engraftment (Caplan, 2009) . Bone marrow stem plasticity may also reflect the developmental origins of bone marrow cells as mesoderm originates from mesothelium via an epithelial-to-mesenchymal transition. The reverse process of mesenchymal-to-epithelial transition may be activated during tissue repair through alteration of key developmental master switch genes in bone marrow MSC on lodgement or engraftment into distant organs and tissues (Phinney and Prockop, 2007) . In summary, bone marrow stem cells are inherently plastic, but the biology of MSC subpopulations needs further characterization in order to settle this controversial issue. The first report on bone marrow cell contribution to human endometrial regeneration demonstrated significant chimerism ranging from 0.2 to 52% in the endometrial glands and stroma of four women who received single antigen HLA mismatched bone marrow transplants (Taylor, 2004) . Most glands consisted entirely of host or donorderived cells indicating monoclonal derivation. However, some individual glands contained a mix of donor and recipient cells (Taylor, 2004) , suggesting that a single gland may comprise multiple clones. A similar study of the endometrium from three women who had received gender mismatched bone marrow transplants also demonstrated chimeric endometrial glands containing a Y chromosome in 0. the epithelial cells (Ikoma et al., 2009 (Mints et al., 2008) . In a transgenic mouse bone marrow transplant model, estrogen promoted donor endothelial progenitor cell migration into the endometrium and their incorporation into blood vessels (Masuda et al., 2007a) . It is not known if the source of donor bone marrow cells contributing to chimeric endometrial tissue is haemopoietic stem cells, MSC, endothelial progenitor or myeloid cells. Of interest is that activation of the PKA pathway induced bone marrow-derived MSC to differentiate into endometrial fibroblast lineage in vitro (Aghajanova et al., 2010) . These cells showed characteristic decidual cell morphology and expressed typical decidual markers, suggesting that bone marrow-derived MSC have the capacity to differentiate into endometrial stromal cells.
Further evidence of a bone marrow source of endometrial decidual cells comes from a study in pregnant mice, previously transplanted with bone marrow cells carrying a transgenic marker, which demonstrated chimeric decidua (Lysiak and Lala, 1992) . Mouse studies also indicate a contribution of bone marrow-derived cells to endometrial repair. In a gender mismatch bone marrow transplant model, endometrial epithelial cells of recipient mice comprised ,0.01% XY + cytokeratin positive cells and ,0.1% XY + stromal cells . Bone marrow cell contribution to endometrial repair is very modest and engraftment of the endometrium seems more likely during regeneration after injury. In a novel double reporter CD45/Cre-Z/EG transgenic mouse model used to track the fate of CD45 + green fluorescent protein (GFP) cells, circulating CD45
+ bone marrow cells contributed small numbers of GFP + endometrial luminal epithelial cells, ranging from 0% in 6-week to 6% in 20-week-old mice (Bratincsak et al., 2007) . GFP + cells appeared as single cells and small clusters. Surprisingly, the number of GFP + cells increased to 82% in the one pregnant mouse examined. Although small numbers of animals were examined, these data suggest increasing incorporation and limited clonal expansion of bone marrow-derived cells into the endometrial epithelium over time. Confirmatory studies are required to verify these findings. The lack of CD45 expression observed in epithelial and stromal LRC may be due to transdifferentiation into endometrial cells. It is too early to draw conclusions on whether endometrial cells are derived from bone marrow cells or resident stem cells, or if both sources contribute. The vascular location of endometrial SP cells ( Fig. 5C and D) and the fact that eMSC are perivascular cells (see below) suggests that the endometrial stem cell niche is associated with blood vessels, a convenient portal of entry for bone marrow-derived cells. It is also unclear if an ultimate endometrial stem cell exists that has capacity to replace all endometrial cells, including epithelial, stromal and vascular cells, or whether there are separate epithelial progenitor cells and MSC. To date, the data suggest that there are possibly three distinct endometrial stem/progenitor cells, an epithelial progenitor cell, an eMSC and an endothelial progenitor cell.
New developments
Markers identifying mesenchymal/stromal stem cells in human endometrium
In a major breakthrough, eMSC were recently isolated from human endometrium by their co-expression of two perivascular cell markers, CD146 and PDGF-receptor-b (PDGF-Rb; Schwab and Gargett, 2007 (Fig. 6A-F) . The CD146 + PDGF-Rb + cells expressed typical MSC surface markers, CD29, CD44, CD73, CD90 and CD105 and were negative for haemopoietic and endothelial markers . However, STRO-1, a marker used to prospectively isolate bone marrow-derived MSC (Gronthos and Simmons, 1995; Shi and Gronthos, 2003) was not expressed by CD146 + PDGF-Rb + cells, nor by clonogenic stromal CFU (Schwab et al., 2008) . The CD146 + PDGF-Rb + cells underwent multilineage differentiation into adipogenic, myogenic, chondrogenic and osteoblastic lineages when cultured in appropriate induction media . CD146 + PDGF-Rb + cells were located perivascularly in both functionalis and basalis layers of human endometrium ( Fig. 6G ; Schwab and Gargett, 2007) . The CD146 + PDGF-Rb + subpopulation of endometrial stromal cells appear to be similar to bone marrow and adipose tissue MSC in differentiation potential and perivascular location identified for MSC in many organs (Crisan et al., 2008) . MSCA-1, a bone marrow-derived MSC surface marker recently identified as Tissue Non-specific Alkaline Phosphatase (TNAP), also immunolocalizes to a perivascular location in human endometrium (Fig. 6H -J) , suggesting that this single marker may be useful for the prospective isolation of eMSC (Sobiesiak et al., 2009) . However, TNAP also localizes to endometrial epithelium, and a second marker (e.g. EpCAM) is needed to exclude the epithelial cells.
A major advantage of being able to partially purify fresh eMSC is that their molecular features can be characterized in non-cultured cells, and their utility in cell-based therapies for regenerative medicine evaluated in pre-clinical disease models.
Expression of stem cell markers in endometrium
Immunotechniques have been used to examine stem cell marker expression in human and mouse endometrium. Oct-4 (POU5F1), a marker of pluripotent human embryonic stem cells and some adult stem cells, was demonstrated in some human endometrial tissues, but the cell types and location were not determined (Matthai et al., 2006) in some mouse stromal LRC (Cervello et al., 2007) .
Musashi-1, an RNA-binding protein in neural stem cells and an epithelial progenitor cell marker that regulates self-renewal signalling pathways, was recently immunolocalized to single epithelial cells and small clusters of stromal cells in human endometrium (Gö tte et al., 2008) . Musashi-1 + cells were mainly found in the basalis in the proliferative stage of the menstrual cycle, suggesting their possible stem/ progenitor cell function. Stromal Musashi-1 + cells were not found in a perivascular location, although some were in a periglandular region, a similar location to some stromal LRC in mouse endometrium co-expressing CD7 and CD56 have been identified in human endometrial cell suspensions and may be lymphoid progenitors (Lynch et al., 2007) . Whether these cells function as haemopoietic stem cells and generate endometrial leucocytes in the endometrium or contribute to the SP population is unknown. Neither is it known whether the cells expressing these markers function as endometrial stem/progenitor cells (Gargett, 2007) . The orphan receptor and Wnt target gene, leucine-rich repeatcontaining G protein-coupled receptor-5 (Lgr-5) has recently been identified as a marker of mouse small intestine and colon epithelial stem cells located in the intestinal crypts (Barker et al., 2007) . Using genetic lineage tracing, Lgr-5-expressing cells were shown to generate all epithelial lineages in the intestine and hair follicles. Lgr5 is dynamically regulated in endometrial epithelium, expressed only in immature and ovariectomized mice, and down-regulated by estrogen (Sun et al., 2009) .
LGR5 is also expressed in human endometrial epithelium (Krusche et al., 2007) . The utility of LGR5 as a marker of human endometrial epithelial progenitor cells requires the development of quality antibodies to a surface epitope to purify the cells for subsequent assessment of adult stem cell function.
Stem/progenitor cells in menstrual blood
Given that CD146 + PDGF-Rb + eMSC and ABCG2 + SP cells have been identified in both functionalis and basalis Masuda et al., 2010) , it is not surprising that emerging evidence suggests that endometrial stem/progenitor cells are shed in menstrual blood (Cui et al., 2007; Meng et al., 2007; Patel et al., 2008; Hida et al., 2008) . Stromal cells have been cultured from menstrual blood in a manner similar to bone marrow-derived MSC, but interestingly epithelial cells have either been overlooked, overgrown by stromal cells (Musina et al., 2008) or not been retrieved, indicating that epithelial progenitors are more likely resident in the basalis layer and are not normally shed during menstruation. Adherent cells cultured from menstrual blood rapidly expand with a doubling rate of 18 -36 h (Meng et al., 2007; Patel et al., 2008) , undergoing 25-30 population doublings (Hida et al., 2008) . Several clonogenic cell lines have been established by single cell plating in one case and these maintained a stable karyotype for up to 68 population doublings (Meng et al., 2007) . Cultured menstrual blood MSC (mbMSC) (also termed endometrial regenerative cells and menstrual blood stromal stem cells) had a fibroblastic appearance and expressed similar phenotypic surface markers to clonogenic and CD146
+-
PDGF-Rb
+ eMSC, and similarly lacked haemopoietic, endothelial and other stem cell (CD133, Stro-1) markers (Cui et al., 2007; Meng et al., 2007; Hida et al., 2008; Patel et al., 2008) . Several notable differences in the cell surface phenotype on mbMSC was observed in different laboratories for c-kit, CD13 and CD9 markers (Cui et al., 2007; Patel et al., 2008) . This disparity is likely due to the heterogeneity of the menstrual blood cell population, differences in cell selection processes and culture media used. The pluripotency marker OCT4 was expressed in several menstrual blood cell lines, but there was variation in the expression of other markers, i.e. Nanog and SSEA-4 (Meng et al., 2007; Patel et al., 2008) . They also expressed hTERT and demonstrated telomerase activity. Cultured mbMSC expressed HLA-class I but not class II molecules (Cui et al., 2007; Patel et al., 2008) and appear to be of low immunogenicity when transplanted into immunocompetent mice (Murphy et al., 2008) . They are likely to have immunomodulatory properties as preliminary data indicated that mbMSC suppressed the mixed lymphocyte reaction through inhibition of interferon-g and promotion of IL-4 production (Murphy et al., 2008) . Cells cultured from menstrual blood have broad differentiation capacity producing all the mesodermal lineages including skeletal and cardiac muscle cells (Cui et al., 2007; Hida et al., 2008) , but also neural lineages . Co-culturing mbMSC with fetal mouse cardiomyoctes produced spontaneously beating cells expressing cardiac muscle markers, troponin-I and a-actinin as striations (Hida et al., 2008) . Recorded action potentials demonstrated typical cardiac muscle 'pacemaker' potentials. Our own unpublished studies have also demonstrated that menstrual blood contains clonogenic, multipotent cells with MSC activity (Anwar et al., 2008) . There is an emerging interest in using mbMSC for cell-based therapies (see below), and several companies offer mbMSC banking services to women.
Cancer stem cells in endometrial cancer
Cell populations in cancer tissues are heterogeneous with respect to marker expression, gene profiles, proliferation potential and differentiation abilities, leading to the concept that tumours resemble an organ comprising a hierarchy of cells including a small population of cancer stem cells (CSC) (Visvader and Lindeman, 2008) . CSC are similar to adult stem cells possessing key properties of self-renewal and differentiation, but their function is no longer controlled by the stem cell niche (Pardal et al., 2003) . As a result, the frequency of CSC may be increased in tumours compared with their normal adult stem cell counterparts due to faulty or absent niche regulation of their proliferative activity (Rosen and Jordan, 2009 ). CSC are detected as self-renewing tumour-initiating cells (TIC) in serial transplantation assays, but they may not have acquired the initial genetic mutation leading to tumourigenesis (Visvader and Lindeman, 2008) . However, CSC maintain the tumour producing all the 'differentiated' tumour cells comprising the bulk of the tumour. CSC are also responsible for key features of cancers including metastasis and chemo-and radio-resistance. Continued acquisition of genetic and epigenetic mutations can create new CSC, which may co-exist or overtake existing CSC as the tumour progresses (Visvader and Lindeman, 2008) . CSC may be derived from normal adult stem cells that have attained inactivating mutations in tumour suppressor genes, or from differentiated cells through mutations that activate self-renewal signalling pathways (Rosen and Jordan, 2009 ).
CSC activity in endometrial cancer
A role for CSC has been demonstrated for breast cancer, acute myeloid leukaemia, prostate cancer and glioblastoma (Pardal et al., 2003) and more recently in endometrial cancer (Friel et al., 2008; Hubbard et al., 2009; Kato et al., 2010) . In a comprehensive study of 34 samples from both types and all grades of endometrial cancer, a small population (,1%) of clonogenic tumour cells (CFU) were identified that could be serially cloned in vitro, indicating self-renewal capacity (Hubbard et al., 2009 ). There was a trend of increasing selfrenewal with increasing tumour grade. Several self-renewal genes were expressed in the secondary clones including BMI-1, SOX-2, NANOG and b-CATENIN. Freshly isolated endometrial cancer cells transplanted in limiting dilution into immunocompromized NOD/Scid mice initiated tumours (Fig. 7) recapitulating parent tumour histoarchitecture and marker expression with as few as 1/10 000 cells in 50% of transplants indicating that a small population of TIC or CSC differentiated in vivo. These tumours were serially transplanted up to five times requiring fewer cells with increasing passage, but maintained the histopathological features and pattern of marker expression (ERa, PR cytokeratin and vimentin) as the original tumour ( Fig. 7 ; Friel et al., 2008; Hubbard et al., 2009 ).
Endometrial stem/progenitor cells
SP cells in endometrial cancer
SP cells have been identified in several low-and high-grade endometrioid endometrial cancer samples and several human endometrial cancer cell lines (Ishikawa, AN3CA, Hec1) (Friel et al., 2008; Kato et al., 2010) . Further investigation of the cancer cell lines showed that the Hec1 SP population was clonogenic and self-renewed in the serial cloning assay, and initiated larger tumours than the non-SP population when transplanted into mice (Kato et al., 2010) . Similarly AN3CA SP cells, but not the non-SP population, were clonogenic, resistant to paclitaxel and contained a population of TIC that could be serially transplanted up to four times (Friel et al., 2008) . Interestingly, the Hec1 SP cells produced tumours comprising epithelial tumour cells and human vimentin-and a-smooth muscle actin-expressing stromal cells, indicating that an epithelial to mesenchymal transition had occurred during cancer progression of the SP cell-initiated tumours in vivo (Kato et al., 2010) .
Markers of endometrial CSC
The first surface marker used to identify CSC in human endometrial cancer is the CD133/1 epitope. In a study examining 113 patient samples covering the full spectrum of endometrial cancer (Rutella et al., 2009) , it was shown that CD133 + endometrial cancer cells had higher cloning efficiency, proliferated at a faster rate, particularly in the presence of estradiol, and were less sensitive to several chemotherapeutic agents compared with the CD133 2 population. Endometrial cancer cells were cultured as tumour spheres which maintained CD133 expression for 12 weeks. In contrast to normal mouse endometrial epithelial LRC, which do not express ERa , endometrial cancer CD133 + cells showed higher expression levels of ERa than CD133 2 cells, but it is not known if niche cells were included in the analysis. Interestingly both CD133 + and CD133 2 endometrial cancer cells produced tumours of similar size when transplanted into mice (Rutella et al., 2009) . This data suggests that endometrial CSC may be enriched in the CD133 + fraction, although TIC were also found in CD133 2 cell fraction and further evidence is required to determine if CD133 defines endometrial CSC (Hubbard and Gargett, 2010) . Once endometrial CSC are defined and characterized, and their role in endometrial cancer development confirmed, it will be possible to design new treatments targeting this population, but sparing normal endometrial stem/progenitor cells (Hubbard and Gargett, 2010) .
Clinical applications and future research
Endometrial stem/progenitor cells in endometriosis
The pathogenesis of endometriosis is poorly understood. The most widely accepted mechanism is Sampson's retrograde menstruation theory where viable endometrial fragments refluxed into the pelvic cavity, attach to and invade the peritoneal mesothelium to establish ectopic growth of endometrial tissue (Giudice and Kao, 2004) . It is not known why only 6-10% of women develop endometriosis when retrograde menstruation occurs in most women. An attractive hypothesis is that endometrial stem/progenitor cells are abnormally shed during menses, gaining access to the peritoneal cavity where they establish ectopic implants in those women who develop endometriosis ( Fig. 8 ; Starzinski-Powitz et al., 2001; Leyendecker et al., 2002; Gargett, 2006; Gargett, 2007; Sasson and Taylor, 2008) . It is possible that long-term endometriotic lesions develop from endometrial stem/ progenitor cells, while those that resolve may have established from mature transit-amplifying cells. Alternatively, endometrial stem/ progenitor cells, with yet to be identified intrinsic abnormalities, may have increased propensity to implant and establish an ectopic colony, or normal stem/progenitor cells implant more readily on an abnormal peritoneal mesothelium. No direct evidence for the role of endometrial stem/progenitor cells in the pathogenesis of endometriosis has been reported to date, however, numerous studies demonstrate that unfractionated human endometrial cells establish ectopic endometrial growth in the many models used for the study of endometriosis (Masuda et al., 2007b; Sasson and Taylor, 2008) . In baboons which menstruate, shed menstrual debris induces endometriosis spontaneously or under experimental conditions ( Fazleabas et al., 2002) , suggesting the presence of stem/progenitor cells in the debris. It is not known if there are differences in the numbers of clonogenic MSC-like cells shed in menstrual blood between women with and without endometriosis, or whether women susceptible to endometriosis may have a higher propensity to shed endometrial stem/ progenitor cells. Neither is it known whether endometrial stem/ progenitor cells are shed in a retrograde manner in women with endometriosis. A recent study assessing the peritoneal fluid of women with and without endometriosis at different stages of the cycle found no increase in endometrial cells in the peritoneal fluid during menstruation or in women with endometriosis (Bokor et al., 2009) . A difficulty, experienced by this and previous studies examining peritoneal fluid for refluxed endometrial cells, is that multiple markers are required to distinguish endometrial epithelial and stromal cells, mesothelial cells and leucocyte populations, technically difficult when using immunohistochemical approaches. If stem/progenitor cells are present in retrogradely shed endometrium, their concentrations will be lower compared with that of normal endometrial cells, further challenging the technical ability to identify them. Defining markers of endometrial stem/ progenitor cells becomes essential to undertake this task. If endometrial stem/progenitor cells are shed in retrograde menstrual debris, it is likely they will only establish ectopic lesions when transported with their niche cells (Gargett, 2007) .
Similar to the concept of TIC having CSC properties, it has been postulated that human endometriosis-initiating cells reconstituting ectopic endometriosis implants are likely to be endometrial stem/ progenitor cells . Numerous animal models exist for investigating endometriosis lesion development, and as new more severely immunocompromized mouse strains have been developed, the longer the xenografted tissue survives. The recent use of NOG mice, lacking NK, T and B cells, has demonstrated that ectopic endometrial tissue can grow from transplanted human endometrial cells (Masuda et al., 2007b) . In this model progesterone withdrawal produced a large blood-filled cyst like a red spot lesion of endometriosis on the kidney surface (Fig. 4D) . The mouse kidney parenchyma was invaded by human blood vessels which formed chimeric vessels with the host murine endothelium, providing a murine blood flow to the transplant ( Fig. 4E ; Masuda et al., 2007b) . The angiogenic potential of the endothelial cells present in the grafted endometrial cells is likely crucial for establishment and development of endometriosis, not only because the functional vascularization is required for maintenance of endometriotic lesions but also because the eMSC niche is perivascular . This unique animal model is suitable for studying the role of stem/progenitor cells in the pathogenesis of endometriosis through non-invasive, real-time and quantitative assessment of ectopically reconstituted endometrium-like tissues, and could potentially be applicable for drug testing and gene-target validation in endometriosis (Masuda et al., 2007b) .
Transdifferentiation or adult stem cell plasticity, particularly of bone marrow-derived stem cells, is a controversial concept in the stem cell field. Transdifferentiation is likely mediated by nuclear reprogramming and altered transcriptional activity of key developmental genes. This process is a form of metaplasia resulting from changes in the extracellular environment, and appears to occur in the setting of tissue damage (Tosh and Slack, 2002) . Metaplasia of the peritoneal lining has been suggested as one possible cause of endometriosis. However, another source of the metaplastic cells with the transdifferentiation capacity is bone marrow stem cells that gain access to the pelvic cavity via the circulation. In a mouse transplant model where genetically marked bone marrow-derived cells were tracked, it was demonstrated that a small number incorporated into established endometriosis lesions and transdifferentiated into epithelial (,0.04%) and stromal cells (0.1%) . In this model, the bone marrow-derived cells contributed to endometriosis progression rather than initiating endometriosis lesion development (Du and Taylor, 2010a) .
Changing cell phenotype may involve epithelial mesenchymal transition (EMT) or mesenchymal epithelial transition (MET), processes known to occur during embryogenesis and recapitulated again in carcinogenesis (Polyak and Weinberg, 2009 ). Changing cell phenotypes 
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+ epithelial population, the latter with properties similar to carcinoma micrometastasis (Starzinski-Powitz et al., 2001) . In keeping with the similarity to early carcinoma, endometriotic lesions regress during estrogen depletion therapy but recur on cessation of therapy, suggesting that putative stem/progenitor cells in the lesion remain quiescent or dormant and then reactivate on subsequent estrogen exposure. Endometrial stem/progenitor cells within the lesions may also reseed subsequent lesions. Interestingly, clonogenic endometrial epithelial cells are weakly positive or negative for cytokeratin (Chan et al., 2004) and some SP cells do not express the epithelial maturation marker CD9 (Kato et al., 2007) , also suggesting an EMT in these putative epithelial stem/progenitor cells.
Indirect evidence for a role of endometrial stem/progenitor cells in the pathogenesis of endometriosis
Epithelial cells in some endometriosis lesions are monoclonal (Jimbo et al., 1997) , suggesting a single cell origin and the possibility that the endometriosis-initiating cell is an endometrial stem/progenitor cell. Some endometriotic lesions are polyclonal, suggesting contamination with polyclonal stromal cells, repeated seeding of the lesion with cells from other sources, including the bone marrow, or establishment from fragments of shed endometrium containing several stem/ progenitor cells (Gargett and Guo, 2010) . A careful analysis of microdissected ectopic endometrium has shown multiple monoclonal foci in the lesions (Wu et al., 2003) . Cellular lineages reconstructed from methylation patterns in a menstrual fragment of human endometrium showed greater relatedness to the cells in close proximity than those at greater distances (Wu and Guo, 2008) . Increasing evidence suggests that women with endometriosis have a greater amount of basalis endometrium in their menstrual debris than women without endometriosis (Leyendecker et al., 2002) , possibly due to excessive uterine peristaltic contractions in women with endometriosis (Leyendecker et al., 2004) . This may cause microtrauma to the basalis layer, and increased retrograde transport of basal endometrial fragments into the peritoneal cavity. A larger proportion of menstrual fragments have basalis characteristics in women with endometriosis compared with healthy controls with respect to ER expression. The importance of basalis-type endometrium in endometriotic lesion formation may be related to the greater numbers of stem/progenitor cells in this region (Gargett and Guo, 2010) .
eMSC cells in adenomyosis
Adenomyosis is characterized by the benign invasion of basalis endometrial glands and stroma deep into the myometrium (Ferenczy, 1998) . Smooth muscle hyperplasia is also a feature of adenomyosis. Little is known of the pathophysiology of adenomyosis. It has been postulated that chronic peristaltic myometrial contractions involved in sperm transport cause microtrauma to the endometrial myometrial junction, setting up a cycle of tissue injury and repair enhanced by the local production of estrogen, which in turn promotes hyperperistaltic uterine activity (Leyendecker et al., 2009) . The auto-traumatization allows basal endometrium to penetrate the myometrium and proliferate, producing pockets of adenomyosis deep within uterine muscle. Adult stem cells are frequently activated in tissue injury and it is possible that these have a role in establishing the ectopic lesions, and their abnormal differentiation may be responsible for the smooth muscle hyperplasia (Gargett, 2007) . Alterations to the orientation of endometrial stem/progenitor cell niches may also occur, allowing myometrial invasion (Gargett, 2007) . It was recently shown that stromal cells cultured from adenomyotic tissue undergo multilineage mesodermal differentiation and express MSC surface phenotypic markers (Chen et al., 2010) . It is not known if these adenomyotic stromal cells are clonogenic, self-renew or contain a population of CD146 + PDGF-Rb + cells. However, the gene expression profile of the adenomyotic stromal cells was different from normal endometrial stromal cells, and COX-2 overexpression was identified. COX-2 plays a key role in the tissue injury repair cycle and local production of estrogen (Leyendecker et al., 2009 ). More research is required to establish a role for endometrial stem/ progenitor cells in the initiation and progression of adenomyosis.
eMSC in regenerative medicine
Bone marrow-derived MSC are a particularly attractive source of cells for regenerative medicine (Caplan, 2007) and clinical trials using allogeneic bone marrow-derived MSC for treatment of heart disease, stroke, cartilage repair and spinal cord injury have started. MSC home to sites of tissue damage when infused intravenously, and secrete bioactive molecules that promote tissue repair, with little evidence of engraftment (Prockop, 2009) . In this setting, MSC act in a paracrine manner secreting large quantities of angiogenic, anti-fibrotic, anti-apoptotic, immunosuppressive factors, and other molecules inducing tissue-specific progenitor cell mitosis to promote cellular replacement and angiogenesis, and limit scarring, cell death, immunosurveillance and chronic inflammation; processes that collectively repair damaged tissue (Caplan, 2009 ). The regenerative potential of eMSC was first demonstrated using mbMSC. These were transplanted into immunodeficient mdx mice (model of Duchenne muscular dystrophy), where they incorporated into atrophied skeletal muscle fibres and contributed to muscle repair (Cui et al., 2007) . Both cell fusion and in situ differentiation appeared to be involved. It is not clear whether the reparative effect was due in part to promotion of angiogenesis as the transplanted cells homed to peri-muscle fibre regions where blood vessels are located (Cui et al., 2007) . Other preliminary experiments also suggest that mbMSC might promote angiogenesis and improve critical limb ischaemia induced by femoral artery ligation (Murphy et al., 2008) . Clinical grade menstrual blood-derived endometrial regenerative cells have been tested in a small phase 1 clinical trial of 4 patients with multiple sclerosis, administered by intravenous and intrathecal routes (Zhong et al., 2009) . After 1 year no immunological reactions or other adverse effects were documented. An alternative regenerative medicine approach is to harness the ability of MSC to differentiate into distinct cell types when delivered in tissue-specific scaffolds for tissue engineering applications to repair bone, cartilage, muscle, tendon, fat and other connective tissues (Caplan, 2007) . The scaffolds provide both structural support and cell adhesion substrates allowing large numbers of cells to be delivered directly to the damaged site as a three-dimensional living patch of tissue (Schmidt et al., 2005; Atala, 2009) . MSC are ideal to incorporate into scaffolds because they not only differentiate into soft tissue lineages, but also secrete factors promoting angiogenesis and extracellular matrix regeneration. In a tissue engineering approach using cell sheet technology, EGFP-labelled mbMSC grafted into the myocardial infarct area of recipient nude rat hearts differentiated into troponin-1 + , a-actinin + striated cardiac muscle cells (Hida et al., 2008) . A significant reduction in the myocardial infarct area was observed in the transplanted hearts compared with hearts similarly transplanted with bone marrow-derived MSC, indicating the potency of the menstrual blood cells. Significant improvement of cardiac parameters and a reduction in left ventricular fibrosis was also observed in the menstrual blood cell transplanted hearts (Hida et al., 2008) . Thus mbMSC have considerable cardiomyogenic differentiation capacity and may have potential as a possible therapeutic for cardiac regenerative medicine.
Unresolved questions
Markers for human endometrial epithelial progenitor cells
Since endometrial stem/progenitor cells were only identified in 2004, there remain many unresolved issues in this new field of research. One of the most urgent is to identify surface markers with sufficient specificity to identify endometrial epithelial progenitor cells. At this stage epithelial progenitor cells can only be identified retrospectively in CFU assays. Until epithelial progenitor cells can be reliably distinguished from their mature progeny in the glands and luminal epithelium, their location and role in endometrial proliferative disorders, such as endometriosis, adenomyosis, endometrial hyperplasia and endometrial cancer remain unresolved questions. Neither can the molecular, genetic or epigenetic make-up of endometrial progenitor cells be characterized.
Relationship between cultured endometrial stromal cells and eMSC
Are cultured endometrial and menstrual blood stromal fibroblasts equivalent to mesenchymal stem/stromal cells? Stromal fibroblasts from many tissues have a number of properties identical to MSC, including multilineage differentiation, immunomodulatory properties and surface marker phenotype, while their gene expression profiles are unique, reflecting their tissue of origin (Haniffa et al., 2009) . Certainly stromal fibroblasts cultured from menstrual blood and human endometrium exhibit these typical features of fibroblasts. MSC also exhibit these properties, but in addition are rare, have CFU activity, self-renew and in the bone marrow, they have specialized niche functions. Human endometrium also harbours a rare population with MSC and fibroblast properties that can be partially purified in the CD146 + PDGF-Rb + population. In our experience a much larger proportion of the rare CD146 + PDGF-Rb + cells differentiate than unfractionated fibroblasts and the individual CFU are truly multipotent as their progeny differentiate into multiple mesodermal lineages. This suggests that there is a hierarchy in the MSC-fibroblast lineage. These overlapping functions of stromal fibroblasts and eMSC raise questions as to the necessity of harvesting the rare CFU or CD146 + PDGF-Rb + population for potential use in regenerative medicine. Clearly both populations need further molecular, genetic and in vivo characterization to answer this question.
Endometrial stem cell types and their origin
Another key unanswered question is just how many different stem/ progenitor cell types there are in human endometrium (Table I) ? And what is the relationship between the CFU, SP cells, tissue-reconstituting cells and LRC? Is there a single endometrial stem/progenitor cell? Or are there separate epithelial, stromal, endothelial stem/progenitor cells in human endometrium? The cellular complexity of endometrium, its exquisite sensitivity to sex steroid hormones and its cyclical remodelling makes these questions on stem/progenitor cell a challenge to unravel. They also indicate the importance of finding markers that distinguish the cells types and their position in the cellular hierarchy. Finally, the origin of endometrial stem/progenitor cells remains unresolved. Although there is some evidence for bone marrow as the source of endometrial stem/progenitor cells, what is their relationship to resident stem/progenitor cells that are presumably derived from coelomic epithelium? And what is the role of embryonic processes, such as epithelial to mesenchymal and mesenchymal to epithelial transitions, in generating the adult stem/progenitor cells present in endometrium and potentially in endometrial disorders such as endometriosis? Studies to resolve these issues provide many avenues for continued research in the coming years that will likely lead to the development of new animal models, molecular genetic and epigenetic characterization, and hopefully the emergence of more specific markers to define endometrial stem/progenitor cells. This will in turn allow the possible roles of endometrial stem/ progenitor cells in gynaecological disease to be investigated.
